Natalia Geyvandova
A5050609377- Hepatitis C virus research
- Hepatitis B Virus Studies
- Liver Disease Diagnosis and Treatment
- Liver Disease and Transplantation
- Hepatitis Viruses Studies and Epidemiology
- Cytomegalovirus and herpesvirus research
- Diet, Metabolism, and Disease
- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
- Liver Diseases and Immunity
- Neurological Disorders and Treatments
- Chronic Lymphocytic Leukemia Research
- Trauma, Hemostasis, Coagulopathy, Resuscitation
- Medicinal Plants and Bioactive Compounds
- Organ Transplantation Techniques and Outcomes
- Pharmacological Effects of Natural Compounds
- Cytokine Signaling Pathways and Interactions
- HIV/AIDS drug development and treatment
- Drug-Induced Hepatotoxicity and Protection
- Systemic Lupus Erythematosus Research
- Human Health and Disease
Stavropol Regional Clinical Oncology Center
2022-2025
Stavropol State Medical University
2017-2024
Coinfection with hepatitis D virus (HDV) accelerates the progression of liver disease associated chronic B. Bulevirtide inhibits entry HDV into hepatocytes.In this ongoing phase 3 trial, patients D, or without compensated cirrhosis, were randomly assigned, in a 1:1:1 ratio, to receive bulevirtide subcutaneously at 2 mg per day (2-mg group) 10 (10-mg for 144 weeks no treatment 48 followed by 96 (control group). Patients will complete additional follow-up after end treatment. The primary point...
The National Consensus was prepared with the participation of Medical Association for Study Multimorbidity, Russian Scientific Liver Society, Endocrinologists, Gerontologists and Geriatricians, Society Preventive Cardiology, Professional Foundation Promotion Medicine Fund PROFMEDFORUM. aim multidisciplinary consensus is a detailed analysis course non-alcoholic fatty liver disease (NAFLD) main associated conditions. definition NAFLD given, its prevalence described, methods diagnosing...
Bulevirtide (BLV), a first-in-class entry inhibitor, is approved in Europe for the treatment of chronic hepatitis delta (CHD). BLV monotherapy was superior to delayed at week (W) 48, primary efficacy endpoint, MYR301 study (NCT03852719). Here, we assessed if continued therapy until W96 would improve virologic and biochemical response rates, particularly among patients who did not achieve W24.
Abstract Background Bulevirtide (BLV) is a first-in-class entry inhibitor for chronic hepatitis D (CHD) approved in Europe. Interim results from MYR301 (NCT03852719), phase 3 randomized study, showed monotherapy with BLV 2 mg/d or 10 given subcutaneously was effective and safe over 144 weeks (W). With greater risk of developing cirrhosis HDV than HBV alone, we explore the impact status on efficacy safety through 144W.Table 1.Efficacy at Week based Methods 150 patients CHD were stratified...
Aim . The clinical guidelines are intended to provide information support for making decisions by gastroenterologists, general practitioners and internists that will improve the quality of medical care patients with non-alcoholic fatty liver disease, taking into account latest data principles evidence-based medicine. Key points Clinical contain about current views on etiology, risk factors pathogenesis nonalcoholic peculiarities its course. Also given recommendations methods laboratory...
Introduction. As a result of portal hypertension (sequestration platelets in an enlarged spleen) and liver failure (decreased production thrombopoietin the liver) cirrhosis, thrombocytopenia develops, which is associated with risk periprocedural/perioperative bleeding complications. There are still unresolved questions regarding stratification complications, prognostic role thrombocytopenia, as well need for treatment its methods. Materials The Russian Scientific Liver Society selected panel...
Aim of investigation. To estimate efficacy and safety two pharmacological forms «Phosphogliv» (lyophilizate for intravenous administration capsules) the treatment fatty liver degeneration non-alcoholic etiology. Material methods. Original study included overall 180 patients with nonalcoholic disease that were randomized to basic control groups in ratio 2:1. The group received Phosphogliv 5 mg/day as bolus injection 2 weeks, followed by oral intake capsules t.i.d. 10 weeks (the total duration...
Introduction . The increase in serum transaminases (ALT and AST) the persistence of their high values is associated with morbidity mortality from liver diseases. Bicyclol has anti-inflammatory antioxidant effects, which formed basis for this study. Materials methods study enrolled 51 patients (MELD < 19); hepatitis stage – 84.4%, cirrhosis 15.6%. Treatment: 75 mg/day 12 weeks. Criteria efficacy: dynamics ALT, AST, CRP; general well-being (D-FIS scale). Results After 4 weeks treatment...
Hemostasis disorders in cirrhosis / severe liver disease are complex, as they affect both pro- and anticoagulant factors, well antifibrinolytic components. Most of the tests that used clinical practice to assess coagulation do not take into account compensatory capabilities this system a whole. This document provides guidance for optimal application interpretation global screening assessment hemostasis cirrhosis/severe disease, analysis risk factor spontaneous perioperative hemorrhagic...
Bulevirtide (BLV) is a first-in-class inhibitor for chronic hepatitis delta (CHD). Week (W) 48 primary endpoint analysis MYR301 (NCT03852719), Phase 3 randomized study, showed monotherapy with subcutaneous BLV at 2 or 10mg/d was superior to no active anti–hepatitis virus (HDV) treatment and generally well tolerated. We present findings from the predefined W96 interim analysis.
Background . Alcoholic liver disease (ALD) – is a that leads to the development of cirrhosis (LC) with high mortality rate. N-terminal type lll procollagen peptide (PIIINP) one optimal biomarkers for assessing fibrogenesis. Objective : determine clinical significance PIIINP blood level in patients ALD. Materials and methods. 97 ALD were examined. The age was 48,5±9,9 years, there 30 women, 67 men. Steatosis diagnosed 12 patients, 11 alcoholic hepatitis (AH), 74 LC. In group LC, 16 AH against...
<h3>Background</h3> Bulevirtide (BLV) is conditionally approved in the EU for treatment of chronic hepatitis D (CHD) based on surrogate endpoint results. Virologic responders (VR) to HDV therapy are defined as achieving undetectability or a ≥2-log10 IU/mL decline RNA from baseline (BL). However, it unclear if patients who early virologic nonresponders (NR) will benefit continued therapy. <h3>Methods</h3> MYR301 randomized study: BLV 2mg (Arm B) and 10mg C) 144W. Results participants at 96W...
Bulevirtide (BLV) was conditionally approved in the EU for treatment of chronic hepatitis D virus (HDV) infection (CHD). A 24-week (W) analysis a Phase 3 study (MYR301; NCT03852719) BLV 2 or 10 mg QD demonstrated significantly greater combined virologic/biochemical response (CR) vs control and favorable safety. Patients with CHD (N=150) were randomized 1:1:1: Arm (control), no active anti-HDV 48W followed by 96W (n=51); Arms B C, (n=49) (n=50), respectively, 144W. All arms then entered...